Edition:
India

Athenex Inc (ATNX.OQ)

ATNX.OQ on NASDAQ Stock Exchange Global Select Market

15.90USD
25 Apr 2018
Change (% chg)

-- (--)
Prev Close
$15.90
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
140,236
52-wk High
$20.43
52-wk Low
$11.25

Chart for

About

Athenex, Inc. is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company's technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics. The Company... (more)

Overall

Beta: --
Market Cap(Mil.): $1,004.32
Shares Outstanding(Mil.): 62.54
Dividend: --
Yield (%): --

Financials

BRIEF-Athenex Meets Enrollment Target For Late Stage Breast Cancer Trial

* ATHENEX MEETS ENROLLMENT TARGET FOR ORAXOL PHASE III CLINICAL TRIAL IN METASTATIC BREAST CANCER

15 Feb 2018

BRIEF-Athenex Says Patient Enrollment For Two Late Stage Studies Of Actinic Keratosis Treatment Completed

* ATHENEX ANNOUNCES EARLY COMPLETION OF PATIENTS ENROLLMENT FOR TWO PHASE III CLINICAL STUDIES OF KX2-391 OINTMENT FOR ACTINIC KERATOSIS Source text for Eikon: Further company coverage:

14 Feb 2018

BRIEF-Athenex Announces Pricing Of Offering Of Common Stock

* ATHENEX, INC. ANNOUNCES PRICING OF OFFERING OF COMMON STOCK

25 Jan 2018

BRIEF-Athenex Announces Proposed Offering Of Common Stock

* SAYS OFFERING 4.30 MILLION COMMON SHARES Source text for Eikon: Further company coverage:

22 Jan 2018

BRIEF-Athenex Announces Encouraging Early Clinical Efficacy And Safety Data Of Oraxol

* ATHENEX ANNOUNCES ENCOURAGING EARLY CLINICAL EFFICACY AND SAFETY DATA OF ORAXOL IN CLINICAL TRIAL FOR THE TREATMENT OF BREAST CANCER

22 Jan 2018

BRIEF-Athenex Files For Offering Of Up To 4.3 Million Shares

* ATHENEX INC FILES FOR OFFERING OF UP TO 4.3 MILLION SHARES - SEC FILING Source text : (http://bit.ly/2Dr3FzB) Further company coverage:

22 Jan 2018

BRIEF-Athenex Announces`Results Of First Cohort Of Phase I Clinical Trial Of Gastric Cancer Treatment

* ATHENEX ANNOUNCES ENCOURAGING RESULTS OF THE FIRST COHORT OF PHASE I CLINICAL TRIAL OF ORAXOL AND CYRAMZA® (RAMUCIRUMAB) COMBINATION TREATMENT IN GASTRIC CANCER Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

22 Jan 2018

BRIEF-Athenex Receives Positive Feedback From FDA On The Design Of Phase III Clinical Trial For Oraxol

* ATHENEX RECEIVES POSITIVE FEEDBACK FROM FDA ON THE DESIGN OF PHASE III CLINICAL TRIAL FOR ORAXOL

16 Jan 2018

BRIEF-Athenex Announces Chinese FDA Allowance Of Investigational New Drug Application Of Oraxol To Begin Clinical Trials

* ATHENEX ANNOUNCES CHINESE FDA ALLOWANCE OF INVESTIGATIONAL NEW DRUG APPLICATION OF ORAXOL TO BEGIN CLINICAL TRIALS

08 Jan 2018

BRIEF-Athenex Receives Promising Innovative Medicine Designation From The UK MHRA For Oraxol

* ATHENEX RECEIVES PROMISING INNOVATIVE MEDICINE DESIGNATION FROM THE UNITED KINGDOM MHRA FOR ORAXOL, AN INNOVATIVE ORAL FORM OF PACLITAXEL Source text for Eikon: Further company coverage:

27 Dec 2017

Earnings vs. Estimates